Correspondence re: H. Barthel et al., 3′-Deoxy-3′-[ 18F]fluorothymidine as a New Marker for Monitoring Tumor Response to Antiproliferative Therapy in Vivo with Positron Emission Tomography. Cancer Res., 63: 3791-3798, 2003 [3] (multiple letters)

Cancer Research

Volumn 63, Issue 23, 2003, Pages 8558-8560

  Cobben, David C P ^a,b   Elsinga, Philip H ^b   Van Waarde, Aren ^b   Jager, Pieter L ^b   Barthel, Henryk ^c   Aboagye, Eric ^c   Price, Pat ^c  

^a PET Center

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Hammersmith Hospital Campus   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3' DEOXY 3' FLUOROTHYMIDINE F 18; CARRIER PROTEIN; CISPLATIN; CYCLINE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEMCITABINE; METHOTREXATE; THYMIDINE DERIVATIVE; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; DRUG UPTAKE; HUMAN; LETTER; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME;

DIDEOXYNUCLEOSIDES; DRUG MONITORING; HUMANS; NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0346995209     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (0)